Notice on Convening the 3rd Extraordinary General Meeting in 2025
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
Notice on Convening the 3rd Extraordinary General Meeting in 2025
Filed with SSE · · 6 pages · Chinese
Release
China Resources Double-Crane Pharmaceutical Co., Ltd. on 6ix
Earlier from China Resources Double-Crane Pharmaceutical
- Announcement on the Inclusion of the Company’s Drug in the National Medical Insurance Catalog
- Announcement on Wholly-owned Sub-subsidiary Qinhuangdao Zizhu Pharmaceutical Co., Ltd. Passing GMP Compliance Inspection
- Announcement on Canceling the Board of Supervisors, Amending the Articles of Association and Fully Amending Basic Management Systems
- Announcement on Holding Subsidiary Shuanghe Tian'an Pharmaceutical (Guizhou) Co., Ltd. Receiving the Drug Supplemental Application Approval for Pioglitazone Hydrochloride Dispersible Tablets
- Announcement on Wholly-Owned Subsidiary China Resources Saike Pharmaceutical Co., Ltd. Obtaining the Drug Registration Certificate for Bisoprolol and Amlodipine Tablets
Later from China Resources Double-Crane Pharmaceutical
- Announcement on Obtaining Approval Notice for Drug Clinical Trials for DC6001 Tablets by Wholly-owned Subsidiary Beijing Double-Crane Runchuang Technology Co., Ltd.
- Announcement on Notice to Creditors on Repurchasing and Canceling Some Restricted Stocks to Reduce Registered Capital
- Announcement on Daily Related Party Transactions
- Announcement on Hydroxocobalamin Injection Obtaining Notice of Approval for Drug Clinical Trial
- Announcement on Completion of Fund Filing for the Establishment of Double-Crane Industry Fund
Follow China Resources Double-Crane Pharmaceutical into a list and get an email when it puts out news.
Follow China Resources Double-Crane Pharmaceutical